PetroMed Listed on the Frankfurt Stock Exchange



    PetroMed, PLC (FWB:N1Z) (www.PetroMed.ca), an independent oil and
    gas exploration company, announced today that the Company's common
    stock has been accepted for listing and has begun public trading on
    the Frankfurt Stock Exchange (FSE) and with the DAX Share Index, its
    benchmark index of securities. PetroMed's trading symbol is 'N1Z' and
    the German securities code (WKN) is AOK FRC, which is the equivalent
    of a CUSIP in North America. PetroMed's short term goal is to make
    Israel an independent producer of oil and natural gas curing the
    country's energy deficit, and longer term to help Israel to become a
    net energy exporter.

    "PetroMed's listing on the Frankfurt Stock Exchange will increase
    the profile of the Company with both private and institutional
    investors in Germany and across Europe," said Hagai Amir, CEO,
    Chairman, Founder and Director of the Toronto-based company with
    offices in London and Tel Aviv. "This opportunity to broaden our
    shareholder base comes at an excellent time for PetroMed after having
    received permit approval from the Israel Ministry of National
    Infrastructures to begin exclusive exploratory pursuit of hydrocarbons
    within the identified shallow water prospects offshore Tel Aviv in
    northern Israel."

    PetroMed's share capital comprises approximately 45 million common
    shares issued, on a fully diluted basis, and there are 100 million
    authorized.

    The FSE is the largest of eight German securities exchanges
    operated by Deutsche Borse AG, the world's largest stock exchange
    organization by revenue, profitability and market capitalization. The
    exchange has more than 300 market participants, and it is the world's
    third largest securities exchange in terms of turnover and dealings.

    This communication, and all attachments, are intended to be
    received only by the individual or entity to whom it is addressed and
    contains information that is privileged, confidential and/or subject
    to copyright. Any unauthorized use, copying, review or disclosure is
    prohibited. Please notify the sender immediately if you have received
    this communication in error so that we can arrange for its return.